Published online in Anticancer Research, researchers at the Department of Oncology at St. George’s, University of London studied six different cannabinoids and found each to have anti-cancer action on leukemia cells.
Lead author Wai Liu, Ph.D explained the results of the latest study in Monday’s press release. In the latest study, Dr. Liu’s team decided to focus on cannabinoids that lacked psychoactive activity, including cannabidiol, cannabigerol and cannabigevarin.
“This study is a critical step in unpicking the mysteries of cannabis as a source of medicine. The cannabinoids examined have minimal, if any, hallucinogenic side effects, and their properties as anti-cancer agents are promising.”
The non-psychoactive cannabinoids were shown to inhibit growth of leukemia cells at all stages of the cell cycle. Interestingly, the team observed even greater effects when different cannabinoids were administered together.
Dr. Liu’s next study will investigate the potential of cannabinoids when combined with existing treatments as well as different treatment schedules that could maximize their anti-cancer activity.